Masaru Matsuda, See Remarks at Arcutis Biotherapeutics, Inc. (ARQT), sold 9,989 shares at $25.03 ($250K) on 2026-09-08, disclosed to the SEC on 2026-09-10.
Scheduled sale ($250k) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ARQT | SELL | 2026-05-06 | $192K | — | Filing → |
| ARQT | SELL | 2026-03-03 | $314K | — | Filing → |
| ARQT | SELL | 2026-02-04 | $1.2M | — | Filing → |